Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OKYO OKYO Pharma	$2.99 +3.1%	$2.21	$0.81 ▼ $3.11	$101.18M	-0.09	155,725 shs	308,283 shs
TECX Tectonic Therapeutic	$21.91 -5.9%	$21.60	$13.70 ▼ $61.07	$409.06M	3.17	190,467 shs	88,882 shs
TERN Terns Pharmaceuticals	$5.64 +0.7%	$3.78	$1.87 ▼ $11.40	$492.60M	-0.11	1.45 million shs	1.33 million shs
VIGL Vigil Neuroscience	$8.07 -0.1%	$6.95	$1.31 ▼ $8.10	$384.86M	3.34	706,022 shs	3.94 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OKYO OKYO Pharma	-2.03%	+1.40%	+31.22%	+137.70%	+81.25%
TECX Tectonic Therapeutic	+3.15%	+7.18%	+13.51%	+36.78%	+34.33%
TERN Terns Pharmaceuticals	+6.26%	+14.99%	+43.59%	+132.85%	-41.91%
VIGL Vigil Neuroscience	+0.12%	+0.50%	+2.54%	+372.51%	+92.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OKYO OKYO Pharma	3.1275 of 5 stars	3.5	5.0	0.0	3.1	1.7	0.0
TECX Tectonic Therapeutic	3.0196 of 5 stars	3.7	1.0	0.0	3.3	3.3	0.6
TERN Terns Pharmaceuticals	3.8684 of 5 stars	3.3	1.0	4.1	2.6	3.3	0.0
VIGL Vigil Neuroscience	3.7195 of 5 stars	4.0	5.0	0.0	2.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OKYO OKYO Pharma	3.00	Buy	$7.00	134.11% Upside
TECX Tectonic Therapeutic	3.33	Buy	$83.60	281.56% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	177.04% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	33.83% Upside

Current Analyst Ratings Breakdown

Latest OKYO, TERN, TECX, and VIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	TECX Tectonic Therapeutic	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$76.00
6/6/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/5/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$14.00 ➝ $8.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Neutral	$8.00
5/22/2025	VIGL Vigil Neuroscience	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.20) per share	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$9.54 per share	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.07 per share	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OKYO OKYO Pharma	-$16.83M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
TECX Tectonic Therapeutic	-$57.98M	-$7.31	N/A	N/A	N/A	N/A	-30.13%	-27.52%	8/13/2025 (Estimated)
TERN Terns Pharmaceuticals	-$88.85M	-$1.09	N/A	N/A	N/A	N/A	-28.81%	-27.55%	8/4/2025 (Estimated)
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	8/12/2025 (Estimated)

Latest OKYO, TERN, TECX, and VIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	TECX Tectonic Therapeutic	-$0.98	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	VIGL Vigil Neuroscience	-$0.44	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.29	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	TECX Tectonic Therapeutic	-$1.10	-$0.93	+$0.17	-$0.93	N/A	N/A
5/8/2025	Q1 2025	TERN Terns Pharmaceuticals	-$0.29	-$0.26	+$0.03	-$0.26	N/A	N/A
5/7/2025	Q1 2025	VIGL Vigil Neuroscience	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OKYO OKYO Pharma	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	22.92	22.92
TERN Terns Pharmaceuticals	N/A	30.89	30.89
VIGL Vigil Neuroscience	N/A	2.97	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OKYO OKYO Pharma	2.97%
TECX Tectonic Therapeutic	62.63%
TERN Terns Pharmaceuticals	98.26%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
OKYO OKYO Pharma	40.46%
TECX Tectonic Therapeutic	38.00%
TERN Terns Pharmaceuticals	1.50%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OKYO OKYO Pharma	7	33.84 million	20.15 million	Not Optionable
TECX Tectonic Therapeutic	120	18.67 million	11.58 million	N/A
TERN Terns Pharmaceuticals	40	87.34 million	86.03 million	Not Optionable
VIGL Vigil Neuroscience	40	47.69 million	39.10 million	Not Optionable

OKYO, TERN, TECX, and VIGL Headlines

Recent News About These Companies

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Given Consensus Recommendation of "Hold" by Analysts

July 17 at 3:41 AM | americanbankingnews.com

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

July 14, 2025 | businesswire.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Recommendation of "Hold" from Brokerages

July 12, 2025 | marketbeat.com

Vigil Neuroscience (NASDAQ:VIGL) Stock Price Up 0.4% - Here's What Happened

July 9, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (VIGL) Cash Flow - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - Nasdaq

June 27, 2025 | nasdaq.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?

June 25, 2025 | zacks.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

June 9, 2025 | prnewswire.com

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Vigil Neuroscience halts Phase 2 trial for ALSP treatment

June 5, 2025 | investing.com

Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial

June 5, 2025 | biospace.comB

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...

June 5, 2025 | morningstar.comM

Disappointing results see Vigil Neuro drop iluzanebart development

June 4, 2025 | thepharmaletter.comT

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

June 4, 2025 | prnewswire.com

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

June 4, 2025 | globenewswire.com

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

June 2, 2025 | zacks.com

Stifel cuts Vigil Neuroscience stock rating, lowers target to $8

May 29, 2025 | investing.com

Stifel Downgrades Vigil Neuroscience (VIGL)

May 29, 2025 | msn.com

HC Wainwright & Co. Downgrades Vigil Neuroscience (VIGL)

May 28, 2025 | msn.com

Vigil Neuroscience Analyst Ratings and Price Targets | NASDAQ:VIGL | Benzinga

May 24, 2025 | benzinga.com

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil ...

May 24, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
D-Wave Goes International With South Korea Partnership
By Nathan Reiff | June 23, 2025
View D-Wave Goes International With South Korea Partnership
3 Summer Short-Squeeze Candidates With Catalysts for Covering
By Thomas Hughes | June 30, 2025
View 3 Summer Short-Squeeze Candidates With Catalysts for Covering

OKYO, TERN, TECX, and VIGL Company Descriptions

OKYO Pharma NASDAQ:OKYO

$2.99 +0.09 (+3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$3.02 +0.02 (+0.84%)

As of 05:10 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Tectonic Therapeutic NASDAQ:TECX

$21.91 -1.37 (-5.88%)

Closing price 04:00 PM Eastern

Extended Trading

$21.96 +0.05 (+0.25%)

As of 04:32 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Terns Pharmaceuticals NASDAQ:TERN

$5.64 +0.04 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$5.60 -0.03 (-0.62%)

As of 06:00 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Vigil Neuroscience NASDAQ:VIGL

$8.07 -0.01 (-0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$8.07 +0.00 (+0.06%)

As of 06:10 PM Eastern

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time